% | $
Quotes you view appear here for quick access.

ЕЛН Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • mardermj mardermj Mar 13, 2005 12:09 PM Flag

    biogen's political motives going forwar

    Biogen realizing that Tysabri as a Monotherapy application may not work against profit.

    The deal between BIIB and ELN may not be "off" or depend on dual use therapy, that assumption is not easy to validate because partnering may include either or scenarios where both profit from the viability of the medication regardless of how administered

    We need a wake up call: WHAT is the DEAL? Is it both foot the bill for R and D and share the profits regardless of mono or duality of dosage?

    I think so. I think it doesn't matter.

    Who can validate and site url?